Marpai, Inc 8-K, filed Nov 12, 2024
Marpai, Inc. (MRAI)
About this 8-K
Marpai, Inc filed this 8-K on November 12, 2024, reporting on events of November 11, 2024.
Items reported
- Item 2.02: Financial results
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s Telephone Number, Including
Area Code:
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On November 11, 2024, Marpai, Inc. issued a press release providing selected financial information for the three and nine months ended September 30, 2024. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated by reference into this Item 2.02 in its entirety.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit Number |
Description | |
| 99.1 | Press release of Marpai, Inc. dated November 11, 2024 | |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| MARPAI, INC. | ||
| Date: November 12, 2024 | By: | /s/ Damien Lamendola |
| Name: Damien Lamendola Title: Chief Executive Officer | ||
2
Exhibit 99.1
MARPAI reports Third QUARTER 2024 financial results
Turnaround continues to gain traction
Tampa, November 11, 2024, Marpai, Inc. (“Marpai” or the “Company”) (OTCQX: MRAI), a technology platform company, which operates as a national Third-Party Administrator (TPA) through its subsidiaries and is transforming the $22 billion TPA market by offering affordable, intelligent, healthcare solutions to self-funded employer health plans, announced financial results for the third quarter of 2024. The Company expects to hold a webcast to discuss the results on November 12, 2024.
Q3 2024 Financial Highlights:
| ● | Net revenues were approximately $7.0 million for the three months ended September 30, 2024, down $1.7 million, or 20% lower year over year, compared to the three months ended September 30, 2023. |
| ● | Operating expenses were $10.1 million for the three months ended September 30, 2024, down $5.7 million, or 36% lower year over year compared to the three months ended September 30, 2023. |
| ● | Operating loss was $3.1 million for the three months ended September 30, 2024, lower by $4.0 million, or 57% lower year over year compared to the three months ended September 30, 2023. |
| ● | Net loss was $3.6 million for the three months ended September 30, 2024, lower by $3.7 million, or 51% lower year over year compared to the three months ended September 30, 2023. |
| ● | Basic and diluted earnings per share were ($0.30) for the three months ended September 30, 2024, up $0.68 per share year over year compared to the three months ended September 30, 2023. |
“As you can see from our highlights, we continue to make strong progress with our turnaround efforts. Our goal remains profitability and positive cash flow,” said Damien Lamendola, Chief Executive Officer of Marpai. “We have some exciting developments that we will be announcing in the fourth quarter.”
Webcast and Conference Call Information
Marpai expects to host a conference call and webcast on Tuesday, November 12, 2024, at 8:30 a.m. ET to review the Company’s operational and financial highlights for its third quarter ended September 30, 2024.
Investors interested in listening to the conference call may do so by dialing (800)-836-8184 for domestic callers or +1-646-357-8785 for international callers, or via webcast: https://app.webinar.net/Jd298rR8DBe
About Marpai, Inc.
Marpai, Inc. (OTCQX: MRAI) is a technology platform company which operates subsidiaries that provide TPA and value-oriented health plan services to employers that directly pay for employee health benefits. Primarily competing in the $22 billion TPA sector serving self-funded employer health plans representing over $1 trillion in annual claims. Through its Marpai Saves initiative, the Company works to deliver the healthiest member population for the health plan budget. Operating nationwide, Marpai offers access to leading provider networks including Aetna and Cigna and all TPA services. For more information, visit www.marpaihealth.com, the content of which is not incorporated by reference into this press release. Investors are invited to visit https://www.ir.marpaihealth.com. Investor Relations contact: Steve Johnson steve.johnson@marpaihealth.com
Forward-Looking Statement Disclaimer
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve
significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as “anticipates,”
“expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance,”
“may,” “can,” “could”, “will”, “potential”, “should,” “goal” and
variations of these words or similar expressions. For example, the Company is using forward-looking statements when it discusses that
it continues to make strong progress with its turnaround efforts, that its goal remains profitability and positive cash flow and that
it expects to have some exciting developments that it will be announcing in the fourth quarter. Readers are cautioned not to place undue
reliance on these forward-looking statements, which reflect Marpai’s current expectations and speak only as of the date of this release.
Actual results may differ materially from Marpai’s current expectations depending upon a number of factors. These factors include, among
others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures
and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing
the growth of the business. Except as required by law, Marpai does not undertake any responsibility to revise or update any forward-looking
statements whether as a result of new information, future events or otherwise.
More detailed information about Marpai and the risk factors that may affect the realization of forward-looking statements is set forth in Marpai’s filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov.
###
2
MARPAI, INC. AND SUBSIDIARES
CONDENSED CONSOLIDATED BALANCE SHEET
(in thousands, except share and per share data)
(Unaudited)
| September 30, 2024 | December 31, 2023 | |||||||
| ASSETS: | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 830 | $ | 1,147 | ||||
| Restricted cash | 10,978 | 12,345 | ||||||
| Accounts receivable, net of allowance for credit losses of $0 and $25 | 1,228 | 1,124 | ||||||
| Unbilled receivable | 579 | 768 | ||||||
| Due from buyer for sale of business unit | 500 | 800 | ||||||
| Prepaid expenses and other current assets | 771 | 901 | ||||||
| Total current assets | 14,886 | 17,085 | ||||||
| Property and equipment, net | 514 | 611 | ||||||
| Capitalized software, net | 752 | 2,127 | ||||||
| Operating lease right-of-use assets | 2,192 | 2,373 | ||||||
| Goodwill | — | 3,018 | ||||||
| Intangible assets, net | — | 5,177 | ||||||
| Security deposits | 1,248 | 1,267 | ||||||
| Other long-term asset | 15 | 22 | ||||||
| Total assets | $ | 19,607 | $ | 31,680 | ||||
| LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 3,764 | $ | 4,649 | ||||
| Accrued expenses | 2,957 | 2,816 | ||||||
| Accrued fiduciary obligations | 7,969 | 11,573 | ||||||
| Deferred revenue | 1,390 | 661 | ||||||
| Current portion of operating lease liabilities | 559 | 512 | ||||||
| Current portion of convertible debenture, net | 1,540 | — | ||||||
| Other short-term liabilities | — | 632 | ||||||
| Total current liabilities | 18,179 | 20,843 | ||||||
| Other long-term liabilities | 20,467 | 19,401 | ||||||
| Convertible debenture, net of current portion | 4,072 | — | ||||||
| Operating lease liabilities, net of current portion | 3,257 | 3,684 | ||||||
| Deferred tax liabilities | 1,190 | 1,190 | ||||||
| Total liabilities | 47,165 | 45,118 | ||||||
| COMMITMENTS AND CONTINGENCIES | ||||||||
| STOCKHOLDERS’ (DEFICIT) EQUITY | ||||||||
| Common stock, $0.0001 par value, 227,791,050 shares authorized; 13,747,982 shares and 7,960,938 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | 1 | 1 | ||||||
| Additional paid-in capital | 70,119 | 63,307 | ||||||
| Accumulated deficit | (97,678 | ) | (76,746 | ) | ||||
| Total stockholders’ (deficit) equity | (27,558 | ) | (13,438 | ) | ||||
| Total liabilities and stockholders’ (deficit) equity | $ | 19,607 | $ | 31,680 | ||||
3
MARPAI, INC. AND SUBSIDIARES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
(Unaudited)
| Three Months Ended | ||||||||
| September 30, 2024 | September 30, 2023 | |||||||
| Revenue | $ | 7,008 | $ | 8,729 | ||||
| Costs and expenses | ||||||||
| Cost of revenue (exclusive of depreciation and amortization shown separately below) | 5,033 | 5,691 | ||||||
| General and administrative | 2,813 | 4,986 | ||||||
| Sales and marketing | 345 | 1,842 | ||||||
| Information technology | 1,273 | 1,269 | ||||||
| Research and development | 7 | 267 | ||||||
| Depreciation and amortization | 213 | 927 | ||||||
| Loss on disposal of assets | — | 7 | ||||||
| Loss on sale of business unit | 73 | — | ||||||
| Facilities | 311 | 769 | ||||||
| Total costs and expenses | 10,068 | 15,758 | ||||||
| Operating loss | (3,060 | ) | (7,029 | ) | ||||
| Other income (expenses) | ||||||||
| Other income | 119 | 130 | ||||||
| Interest expense, net | (620 | ) | (383 | ) | ||||
| Foreign exchange (loss) gain | 1 | (14 | ) | |||||
| Loss before provision for income taxes | (3,560 | ) | (7,296 | ) | ||||
| Income tax expense | — | — | ||||||
| Net loss | $ | (3,560 | ) | $ | (7,296 | ) | ||
| Net loss per share, basic & fully diluted | $ | (0.30 | ) | $ | (0.98 | ) | ||
| Weighted average common shares outstanding, basic and diluted | 12,043,931 | 7,479,401 | ||||||
4
MARPAI, INC. AND SUBSIDIARES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
(Unaudited)
| Nine Months Ended | ||||||||
| September 30, 2024 | September 30, 2023 | |||||||
| Revenue | $ | 21,582 | $ | 28,448 | ||||
| Costs and expenses | ||||||||
| Cost of revenue (exclusive of depreciation and amortization shown separately below) | 15,078 | 18,530 | ||||||
| General and administrative | 9,954 | 15,938 | ||||||
| Sales and marketing | 1,383 | 5,494 | ||||||
| Information technology | 3,608 | 4,775 | ||||||
| Research and development | 22 | 1,291 | ||||||
| Depreciation and amortization | 2,078 | 2,974 | ||||||
| Impairment of goodwill and intangible assets | 7,588 | — | ||||||
| Loss on disposal of assets | — | 350 | ||||||
| Loss on sale of business unit | 73 | — | ||||||
| Facilities | 1,197 | 1,918 | ||||||
| Total costs and expenses | 40,981 | 51,270 | ||||||
| Operating loss | (19,399 | ) | (22,822 | ) | ||||
| Other income (expenses) | ||||||||
| Other income | 360 | 231 | ||||||
| Interest expense, net | (1,890 | ) | (1,102 | ) | ||||
| Foreign exchange (loss) gain | (3 | ) | (32 | ) | ||||
| Loss before provision for income taxes | (20,932 | ) | (23,725 | ) | ||||
| Income tax expense | — | — | ||||||
| Net loss | $ | (20,932 | ) | $ | (23,725 | ) | ||
| Net loss per share, basic & fully diluted | $ | (1.96 | ) | $ | (3.62 | ) | ||
| Weighted average common shares outstanding, basic and diluted | 10,697,008 | 6,552,575 | ||||||
5
MARPAI, INC. AND SUBSIDIARES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands, except share and per share data)
(Unaudited)
| Nine Months Ended | ||||||||
| September 30, 2024 | September 30, 2023 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | (20,932 | ) | $ | (23,725 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | 2,078 | 2,974 | ||||||
| Loss on disposal of assets | — | 350 | ||||||
| Loss on sale of receivables | 306 | — | ||||||
| Share-based compensation | 2,786 | 1,837 | ||||||
| Loss on sale of business unit | 73 | — | ||||||
| Common Stock issued to vendors in exchange for services | — | 79 | ||||||
| Amortization of right-of-use asset | 181 | 1,289 | ||||||
| Gain on termination of lease | — | 33 | ||||||
| Impairment of goodwill and intangible assets | 7,588 | — | ||||||
| Non-cash interest | 975 | 1,204 | ||||||
| Amortization of debt discount and debt issuance costs | 128 | — | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable and unbilled receivable | 85 | 639 | ||||||
| Prepaid expense and other assets | 136 | 216 | ||||||
| Due from buyer for sale of business unit | 227 | — | ||||||
| Security deposit | 19 | (16 | ) | |||||
| Accounts payable | (885 | ) | 336 | |||||
| Accrued expenses | 141 | (693 | ) | |||||
| Accrued fiduciary obligations | (3,604 | ) | 853 | |||||
| Operating lease liabilities | (380 | ) | (1,670 | ) | ||||
| Due To related party | — | (3 | ) | |||||
| Other liabilities | 827 | 973 | ||||||
| Net cash used in operating activities | (10,251 | ) | (15,324 | ) | ||||
| Cash flows from investing activities: | ||||||||
| Disposal of property and equipment | — | 27 | ||||||
| Net cash provided by (used in) investing activities | — | 27 | ||||||
| Cash flows from financing activities: | ||||||||
| Proceeds from issuance of common stock in a public offering, net | — | 6,432 | ||||||
| Proceeds from sale of future cash receipts on accounts receivable | 1,509 | — | ||||||
| Proceeds from issuance of convertible debentures | 5,978 | — | ||||||
| Payments of convertible debenture issuance costs | (499 | ) | — | |||||
| Payments to buyer of receivables | (1,816 | ) | — | |||||
| Payments to seller for acquisition | (631 | ) | — | |||||
| Proceeds from issuance of common stock in a private offering, net | 4,026 | — | ||||||
| Net cash provided by financing activities | 8,567 | 6,432 | ||||||
| Net decrease in cash, cash equivalents and restricted cash | (1,684 | ) | (8,865 | ) | ||||
| Cash, cash equivalents and restricted cash at beginning of period | 13,492 | 23,117 | ||||||
| Cash, cash equivalents and restricted cash at end of period | $ | 11,808 | $ | 14,252 | ||||
| Reconciliation of cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheet | ||||||||
| Cash and cash equivalents | $ | 830 | $ | 3,018 | ||||
| Restricted cash | 10,978 | 11,234 | ||||||
| Total cash, cash equivalents and restricted cash shown in the condensed consolidated statement of cash flows | $ | 11,808 | $ | 14,252 | ||||
| Supplemental disclosure of cash flow information | ||||||||
| Cash paid for interest | $ | 1,508 | $ | — | ||||
| Supplemental disclosure of non-cash activity | ||||||||
| Measurement period adjustment to Goodwill | $ | — | $ | 198 | ||||
6